✦ LIBER ✦

A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients

✍ Scribed by Atul Humar; Deepali Kumar; Jutta Preiksaitis; Guy Boivin; Deborah Siegal; Jayne Fenton; Kathy Jackson; Sarah Nia; Dale Lien

Book ID: 114803465
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 89 KB
Volume: 5
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2005.00866.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Valganciclovir for cytomegalovirus proph

Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients

✍ Jeong M. Park; Kathleen D. Lake; Robert J. Fontana 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

We thank Jain et al. for their interest and correspondence regarding our recently published study. 1 The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine sur

Polyfunctional Cytomegalovirus-Specific

Polyfunctional Cytomegalovirus-Specific Immunity in Lung Transplant Recipients Receiving Valganciclovir Prophylaxis

✍ L. D. Snyder; R. Medinas; C. Chan; S. Sparks; W. A Davis; S. M. Palmer; K. J. We 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 605 KB

Valganciclovir is an effective prophylax

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients

✍ Sameh Adel Fayek; Wana Mantipisitkul; Flavia Rasetto; Raghava Munivenkatappa; Ro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB

Cytomegalovirus disease among donor-posi

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis

✍ Dimitra Mitsani; M. Hong Nguyen; Eun J. Kwak; Fernanda P. Silveira; Aniket Vadne 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Cytomegalovirus disease and infection in

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis

✍ A.P. Wiita; N. Roubinian; Y. Khan; P.V. Chin-Hong; J.P. Singer; J.A. Golden; S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

Oral ganciclovir versus valganciclovir f

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients

✍ R.L. Brady; K. Green; C. Frei; P. Maxwell 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB